Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
The database and cloud provider has an enormous opportunity thanks to AI -- but it doesn't come without risk.
Oracle Fin Serv Standalone December 2025 Net Sales at Rs 1,452.70 crore, up 11.28% Y-o-Y Jan 22 2026 01:19 PM Oracle Fin Serv Standalone December 2025 Net Sales at Rs 1,452.70 crore, up 11.28% Y-o-Y ...
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results